Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Files An 8-K Regulation FD DisclosureItem 7.01.
On July19, 2017, Aerie Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the topline 12-month safety results from the Company’s Phase 3 “Mercury 1” registration trial for its product candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 7.01.
On or after July19, 2017, representatives of the Company may present to various investors the information about the topline safety and efficacy results of Mercury 1 described in the slides attached to this report as Exhibit 99.2 hereto, which is hereby incorporated by reference into this Item 7.01.
The information in this Item 7.01 (including Exhibits99.1 and 99.2) is being furnished, not filed, to Regulation FD. Accordingly, the information in this Item 7.01 will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Item 7.01 is not intended to, and does not, constitute a determination or admission by the Company that this information is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
Item 7.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits relating to Item 7.01 shall be deemed to be furnished, and not filed:
| 99.1 | Press Release dated July19, 2017. |
| 99.2 | RoclatanTM Mercury 1 Phase 3 12-month Topline Results. |
AERIE PHARMACEUTICALS INC ExhibitEX-99.1 2 d429549dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Aerie Pharmaceuticals Reports Positive RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results RoclatanTM Successfully Demonstrates a Positive Safety Profile and Efficacy Levels Consistent with Previously Reported Results Conference Call and Webcast Today,…To view the full exhibit click here
About Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan.
